Japanese authorities approve cancer drug by Genmab and Abbvie
Genmab and partner Abbvie have received approval in Japan for Epkinly for the treatment of large B-cell lymphoma, LBCL, in patients who have received at least two prior therapies, Genmab states this in an announcement.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.